Applied Therapeutics (APLT) Competitors $1.07 0.00 (0.00%) Closing price 10/8/2025 04:00 PM EasternExtended Trading$1.05 -0.02 (-1.50%) As of 07:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLT vs. GLUE, RAPT, MLTX, ADCT, PRTC, SLDB, ATXS, UPXI, AUTL, and KRROShould you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include Monte Rosa Therapeutics (GLUE), Rapt Therapeutics (RAPT), MoonLake Immunotherapeutics (MLTX), ADC Therapeutics (ADCT), PureTech Health (PRTC), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), Upexi (UPXI), Autolus Therapeutics (AUTL), and Korro Bio (KRRO). These companies are all part of the "pharmaceutical products" industry. Applied Therapeutics vs. Its Competitors Monte Rosa Therapeutics Rapt Therapeutics MoonLake Immunotherapeutics ADC Therapeutics PureTech Health Solid Biosciences Astria Therapeutics Upexi Autolus Therapeutics Korro Bio Applied Therapeutics (NASDAQ:APLT) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends. Which has more risk and volatility, APLT or GLUE? Applied Therapeutics has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Which has higher valuation & earnings, APLT or GLUE? Monte Rosa Therapeutics has higher revenue and earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApplied Therapeutics$460K334.98-$105.62M-$0.45-2.38Monte Rosa Therapeutics$177.99M2.68-$72.70M$0.3621.42 Does the media refer more to APLT or GLUE? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for Applied Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.00 beat Applied Therapeutics' score of -0.92 indicating that Monte Rosa Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Applied Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Monte Rosa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders have more ownership in APLT or GLUE? 98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is APLT or GLUE more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Applied Therapeutics' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Applied Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Applied TherapeuticsN/A -354.24% -144.16% Monte Rosa Therapeutics 13.58%9.95%6.42% Do analysts rate APLT or GLUE? Applied Therapeutics presently has a consensus price target of $4.13, suggesting a potential upside of 285.51%. Monte Rosa Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 98.88%. Given Applied Therapeutics' higher possible upside, equities analysts plainly believe Applied Therapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryMonte Rosa Therapeutics beats Applied Therapeutics on 11 of the 15 factors compared between the two stocks. Get Applied Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLT vs. The Competition Export to ExcelMetricApplied TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$154.09M$3.35B$6.09B$10.54BDividend YieldN/A2.28%5.69%4.71%P/E Ratio-2.3821.5785.4827.61Price / Sales334.98271.42535.60201.12Price / CashN/A47.1237.9261.55Price / Book2.1810.1412.976.76Net Income-$105.62M-$52.31M$3.30B$275.88M7 Day Performance14.54%5.14%4.35%2.81%1 Month Performance143.07%14.68%9.50%9.24%1 Year Performance-86.97%30.98%84.38%35.42% Applied Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLTApplied Therapeutics3.5426 of 5 stars$1.07flat$4.13+285.5%-86.9%$154.09M$460K-2.3830GLUEMonte Rosa Therapeutics2.1684 of 5 stars$7.54+0.5%$15.33+103.4%+54.2%$464.13M$75.62M20.8890Analyst ForecastRAPTRapt Therapeutics3.4906 of 5 stars$27.69+1.6%$23.50-15.1%+95.7%$457.83M$1.53M-1.9580Analyst ForecastMLTXMoonLake Immunotherapeutics2.9457 of 5 stars$7.02-0.6%$37.00+427.1%-81.7%$452.50MN/A-2.532Analyst ForecastAnalyst RevisionHigh Trading VolumeADCTADC Therapeutics2.8716 of 5 stars$4.02+0.4%$7.75+93.0%+47.9%$451.69M$70.84M-2.56310Analyst ForecastAnalyst RevisionPRTCPureTech Health0.0762 of 5 stars$18.67-1.7%N/A-6.6%$451.25M$4.83M0.00100News CoveragePositive NewsAnalyst ForecastSLDBSolid Biosciences2.7592 of 5 stars$5.76-2.0%$15.00+160.6%-10.9%$448.92M$8.09M-2.06100News CoverageAnalyst ForecastATXSAstria Therapeutics2.5935 of 5 stars$7.68+1.8%$29.50+284.3%-25.1%$434.36MN/A-3.8330News CoverageAnalyst ForecastUPXIUpexi2.7424 of 5 stars$7.25+10.9%$15.50+113.9%+173.7%$424.42M$15.81M0.00130Positive NewsAUTLAutolus Therapeutics3.5361 of 5 stars$1.59-5.1%$9.12+475.4%-56.7%$421.83M$10.12M-1.89330Positive NewsAnalyst ForecastKRROKorro Bio2.18 of 5 stars$44.70+1.8%$86.83+94.3%+30.8%$418.87M$2.27M-4.5870News Coverage Related Companies and Tools Related Companies Monte Rosa Therapeutics Alternatives Rapt Therapeutics Alternatives MoonLake Immunotherapeutics Alternatives ADC Therapeutics Alternatives PureTech Health Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Upexi Alternatives Autolus Therapeutics Alternatives Korro Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLT) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Applied Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Applied Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
